Clinical Safety/Tolerability of HF0220 and Its Effect on Biochemical Markers Relevant to Patients With a Diagnosis of Mild to Moderate Alzheimer' Disease

Trial Profile

Clinical Safety/Tolerability of HF0220 and Its Effect on Biochemical Markers Relevant to Patients With a Diagnosis of Mild to Moderate Alzheimer' Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs HF 0220 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker
  • Sponsors Hunter-Fleming
  • Most Recent Events

    • 23 Oct 2008 Results reported in a Newron media release.
    • 20 Aug 2008 Status changed from recruiting to completed, as reported on ClinicalTrials.gov.
    • 02 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top